[Guidelines for the treatment of childhood IgA nephropathy].
Yoshikawa
Norishige
N
Igarashi
Takashi
T
Ishikura
Kenji
K
Kaku
Yoshitsugu
Y
Nakazato
Hitoshi
H
Kamei
Koichi
K
Kawamura
Tetsuya
T
Nakamura
Hidefumi
H
Yamamoto
Yukari
Y
Nakanishi
Koichi
K
Sako
Mayumi
M
D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage / Q000009:adverse effects; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D000925:Anticoagulants / Q000008:administration & dosage; D002648:Child; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000009:adverse effects; D005922:Glomerulonephritis, IGA / Q000628:therapy*; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D008517:Phytotherapy; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D012720:Severity of Illness Index; D014068:Tonsillectomy
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000925:Anticoagulants; D004365:Drugs, Chinese Herbal; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D010975:Platelet Aggregation Inhibitors; C080903:sairei-to; D011239:Prednisolone